Progress of research on targeted therapy for breast cancer

2016 1 36 1 2 1 2Δ 1. 650118 2. 650223 R737. 9 A 1005-1678 2016 01-0007 - 05 Progress of research on targeted therapy for breast cancer ZENG Jia-jia 1 2 YANG Run-xiang 1 LIU Rong 2Δ 1. Department of Internal Medicine The Third Affiliated Hospital of Kunming Medical University Yunnan Province Tumor Hospital Kunming 650118 China 2. Key Laboratory of Animal Models and Human Disease Mechanism Kunming Institute of Zoology Chinese Academy of Sciences Kunming 650223 China Abstract Breast cancer is the most common malignancies among women in China. Because of the better effectiveness and less side effects than chemo-and radio-therapies targeted therapy against main signaling pathways of breast carcinogenesis and development has become one of the research focuses in breast cancer research field. In this review we summarized current targeted therapies applied clinically and undergone pre-clinical research against variant molecular subtypes of breast cancer and breast cancer stem cells. Keywords breast cancer targeted therapy breast cancer stem cell 70% ~ 80% estrogen receptor ER 2 ER 12. 2% 9. 6% 1 estrogen estrogen receptor ER progesterone receptor PR 2 human epidermal growth receptor 2 HER2 ER luminal A B HER2 Her2 ER PR HER2 Tamoxifen triple-negative breast cancer TNBC 4 3 E2 ER ER 4 90 aromatase inhibitor AI 1 ER 2015FA027 AI Letrozole 2014J048 E-mail E2 18387147154@ 163. com E2 E-mail liurong@ mail. kiz. ac. cn E2 1. 1 20 70 AI 7

2016 1 36 ER ER 5 17 15% ~ 25% HER2 1. 2 / 18 1. 2. 1 2 human epidermal growth factor receptor2 HER2 HER2 ER + /HER2 + HER2 Herceptin 1998 HER2 MCF-7 HER2 6 HER2 19 ER ER 7 HER2 ER HER-2 HER2 ER ER 8 HER2 AKT MAPK TAnDEM 2. 2 HER2 III HER1 HER2 HER1 HER2 progression-free survival PFS 4. 8 42. 7% 2. 4 20. 3% 9 ER + / HER2 + Ⅲ PFS CBR PFS 26% 20 8. 2 28% 3 15% 10 1. 2. 2 epidermal growth factor receptor EGFR EGFR HER2 Pertuzumab HER2 MAPK ER HER2 HER2 MCF-7 EGFR HER3 EGFR-HER2 HER2 ERK1 /2 11 Gutteridge E 12 Ⅱ HER2 ER PFS 18. 5 vs 12. 4 22 FDA 53. 6% ER 11. 5% 1. 2. 3 PI3K-Akt-mTOR PI3K-Akt-mTOR 23 T-DM1 MCC 70% PI3K-Akt 13 DM1 Maytansine ER 16 mtor T-DM1 FK506-12 FKBP12 24 2013 2 FDA T-DM1 HER2 mtorc-1 TAMRAD ER 3 II 10% ~ 17% 61. 1% vs 42. 1% 14 mtor PI3K mtor TNBC 15 2 2 human epidermal growth factor receptor 2 HER2 2. 1 Trastuzumab Lapatinib HER2 Ⅲ 21 CLEOPATRA Ⅲ HER2 triple-negative breast cancer TNBC 25 TNBC TNBC TNBC HER2 16 3. 1 ADP- poly ADP-ribose polymerase PARP HER2 PARP DNA PARP EGFR PARP inhibitor PARPI BRCA1 /2 DNA 8

2016 1 36 PARP TNBC Notch Wnt Hsp27 BCSC I PARPI 38 Olaparib DNA Qiu 39 Notch1 mabs CD44 + / TNBC 26 CD24 low TNBC II PARPI Iniparib PFS overall survival OS 27 3. 2 vascular endothelial growth factor VEGF 40 Wnt VEGF Wnt1 28 Bevacizumab VEGF-A 41 Wnt Wnt 29 RIBBON-2 42 TNBC 27 heat shock protein 27 Hsp27 ATP Hsp PFS 5. 1 7. 2 Hsp27 overall remission OR 10% 30 - epithelial-mesenchymal 3. 3 epidermal growth factor receptor EGFR EGFR MAP 32 androgen receptor AR 70% 1 Fan L Strasser-Weippl K Li JJ et al. Breast cancer in China J. 33 TNBC AR 30% AR Wnt /β-catenin JAK /STAT3 MAPK Notch 34 of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast CD44 + /CD24 low CD44 + /CD24 low TNBC Notch γ GSIS Notch GSIS PF- 03084014 transition EMT NF-κB Hsp27 43 Hsp27 AKT VM Cetuximab 5 EGFR EGFR EGFR HER2 TNBC TNBC EGFR TNBC PARP VEGF EGFR EGFR TNBC 3. 4 TNBC TNBC PI3K PTEN INPP4B PI3K PI3K PARP Lancet Oncol 2014 15 7 e279-e289. 2 Kazi AA Gilani RA Schech AJ et al. Nonhypoxic regulation and role AR ER /PR Ⅱ cancer J. Breast Cancer Res 2014 16 1 R15. clinical benefit 3 Harper MJ Walpole AL. A new derivative of triphenylethylene effect rate CBR PFS 35 on implantation and mode of action in rats J. J Reprod Fertil 1967 13 1 101-119. 4 4 Davies C Godwin Gray J R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen patient-level meta-analysis of randomised trials J. Lancet 2011 378 9793 771-784. 36 5 Roop RP Ma CX. Endocrine resistance in breast cancer molecular breast cancer stem cell BCSC pathways and rational development of targeted therapies J. Future Oncol 2012 8 3 273-292. 6 Kurokawa H Lenferink AE Simpson JF et al. Inhibition of HER2 / neu erbb-2 and mitogen-activated protein kinases enhances tamoxifen G2 /M action against HER2-overexpressing tamoxifen-resistant breast cancer 37 BCSC cells J. Cancer Res 2000 60 20 5887-5894. 9

2016 1 36 7 Kato S Endoh H Masuhiro Y et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase J. Science 1995 270 5241 1491-1494. 8 Lee H Jiang F Wang Q et al. MEKK1 activation of human estrogen 15 Ogita S Lorusso P. Targeting phosphatidylinositol 3 kinase PI3K -Akt beyond rapalogs J. Target Oncol 2011 6 2 103-117. 16 Press MF Cordon-Cardo C Slamon DJ. Expression of the HER-2 /neu proto-oncogene in normal human adult and fetal tissues J. Oncogene 1990 5 7 953-962. 17 Ross JS Slodkowska EA Symmans WF et al. The HER-2 receptor and breast cancer ten years of targeted anti-her-2 therapy and personalized medicine J. Oncologist 2009 14 4 320-368. 18 Figueroa-Magalhaes MC Jelovac D Connolly RM et al. Treatment of HER2-positive breast cancer J. Breast 2014 23 2 128-136. 19 Smith I Procter M Gelber RD et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer a randomised controlled trial J. Lancet 2007 369 9555 29-36. 20 Di Leo A Gomez HL Aziz Z et al. Phase III double-blind randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer J. J Clin Oncol 2008 26 34 5544-5552. 21 de Azambuja E Zardavas D Lemort M et al. Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer the LAPTEM trial J. Ann Oncol 2013 24 12 2985-2989. 22 Baselga J Swain SM. CLEOPATRA a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer J. Clin Breast Cancer 2010 10 6 489-491. 23 Sendur MA Aksoy S Altundag K. Pertuzumab-induced cardiotoxicity safety compared with trastuzumab J. Future Oncol 2015 11 1 13-15. 24 Barginear MF John V Budman DR. Trastuzumab-DM1 a clinical receptor alpha and stimulation of the agonistic activity of 4- update of the novel antibody-drug conjugate for HER2-overexpressing hydroxytamoxifen in endometrial and ovarian cancer cells J. Mol breast cancer J. Mol Med 2012 18 1473-1479. Endocrinol 2000 14 11 1882-1896. 25 Carey LA Dees EC Sawyer L et al. The triple negative paradox 9 Kaufman B Mackey JR Clemens MR et al. Trastuzumab plus primary tumor chemosensitivity of breast cancer subtypes J. Clin anastrozole versus anastrozole alone for the treatment of postmenopausal Cancer Res 2007 13 8 2329-2334. women with human epidermal growth factor receptor 2-positive hormone 26 Fong PC Boss DS Yap TA et al. Inhibition of poly ADP-ribose receptor-positive metastatic breast cancer results from the randomized phase III TAnDEM study J. J Clin Oncol 2009 27 33 polymerase in tumors from BRCA mutation carriers J. N Engl J Med 2009 361 2 123-134. 5529-5537. 27 Liang H Tan AR. Iniparib a PARP1 inhibitor for the potential 10 Schwartzberg LS Franco SX Florance A et al. Lapatinib plus treatment of cancer including triple-negative breast cancer J. letrozole as first-line therapy for HER-2 + hormone receptor-positive metastatic breast cancer J. Oncologist 2010 15 2 122-129. IDrugs 2010 13 9 646-656. 28 Fan X Krieg S Kuo CJ et al. VEGF blockade inhibits angiogenesis 11 Shou J Massarweh S Osborne CK et al. Mechanisms of tamoxifen and reepithelialization of endometrium J. FASEB J 2008 22 10 resistance increased estrogen receptor-her2 /neu cross-talk in ER / HER2-positive breast cancer J. J Natl Cancer Inst 2004 96 12 3571-3580. 29 Carey LA. Directed therapy of subtypes of triple-negative breast 926-935. cancer J. Oncologist 2011 16 Suppl 71-78. 12 Gutteridge E Agrawal A Nicholson R et al. The effects of gefitinib 30 Brufsky AM Hurvitz S Perez E et al. RIBBON-2 a randomized in tamoxifen-resistant and hormone-insensitive breast cancer a phase II study J. Int J Cancer 2010 126 8 1806-1816. double-blind placebo-controlled phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second- 13 Lopez-Knowles E O' Toole SA Mcneil CM et al. PI3K pathway line treatment of human epidermal growth factor receptor 2-negative activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality J. Int J Cancer 2010 126 5 1121-1131. 14 Baselga J Campone M Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer J. N Engl J Med 2012 366 6 520-529. metastatic breast cancer J. J Clin Oncol 2011 29 32 4286-4293. 31 Dc K Rs F Md M. Comprehensive molecular portraits of human breast tumours J. Nature 2012 490 7418 61-70. 32 Juvekar A Burga LN Hu H et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer J. Cancer Discov 2012 2 11 1048-1063. 33 Mcnamara KM Yoda T Miki Y et al. Androgen receptor and enzymes in lymph node metastasis and cancer reoccurrence in triplenegative breast cancer J. Int J Biol Markers 2015 30 2 e184-e189. 34 Anestis A Karamouzis MV Dalagiorgou G et al. Is androgen receptor targeting an emerging treatment strategy for triple negative breast cancer J. Cancer Treat Rev 2015 41 6 547-553. 35 Gucalp A Tolaney S Isakoff SJ et al. Phase II trial of bicalutamide in patients with androgen receptor-positive estrogen receptor-negative metastatic Breast Cancer J. Clin Cancer Res 2013 19 19 5505-5512. 36 Wicha MS Liu S Dontu G. Cancer stem cells an old idea--a paradigm shift J. Cancer Res 2006 66 4 1883-1890 1895-1896. 37 Sajadian S Vatankhah M Majdzadeh M et al. Cell cycle arrest and apoptogenic properties of opium alkaloids noscapine and papaverine on breast cancer stem cells J. Toxicol Mech Methods 2015 25 5 388-395. 38 Beug H. Breast cancer stem cells eradication by differentiation therapy J. Cell 2009 138 4 623-625. 39 Qiu M Peng Q Jiang I et al. Specific inhibition of Notch1 signaling enhances the antitumor efficacy of chemotherapy in triple negative breast cancer through reduction of cancer stem cells J. Cancer Lett 2013 328 2 261-270. 40 Zhang CC Yan Z Zong Q et al. Synergistic effect of the gamma- 10

2016 1 36 secretase inhibitor PF-03084014 and docetaxel in breast cancer models J. Stem Cells Transl Med 2013 2 3 233-242. 41 Vaillant F Asselin-Labat ML Shackleton M et al. The mammary progenitor marker CD61 / beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis J. Cancer Res 2008 68 19 7711-7717. 42 Lu D Choi MY Yu J et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells J. Proc Natl Acad Sci U S A 2011 108 32 13253-13257. 43 Wei L Liu TT Wang HH et al. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelialmesenchymal transition and nuclear factor-kappab J. Breast Cancer Res 2011 13 5 R101. 44 Lee CH Wu YT Hsieh HC et al. Epidermal growth factor /heat shock protein 27 pathway regulates vasculogenic mimicry activity of breast cancer stem /progenitor cells J. Biochimie 2014 104 117-126. 2016 2016 1 26 9 16 2015 2016 2016 11